Analyst Yaron Werber of TD Cowen maintained a Buy rating on Ascendis Pharma, retaining the price target of $325.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Yaron Werber has given his Buy rating due to a combination of factors pointing to durable demand and attractive growth in Ascendis Pharma’s core endocrine franchise. Survey work from physicians, payors, and investors indicates that Yorvipath is gaining traction in hypoparathyroidism, with treating endocrinologists forecasting a steady rise in market share over the next several years.
Werber also highlights the early but compelling outlook for Yuviwel in achondroplasia and hypochondroplasia, where its weekly dosing and ease of use are expected to drive meaningful share gains versus the current standard of care. While higher gross-to-net discounts and FX headwinds are likely to weigh on near-term reported Yorvipath revenue versus consensus, his analysis suggests that the underlying prescription momentum, combined with the ramp of Yuviwel (and potential Skytrofa contribution), supports a favorable long-term revenue and earnings trajectory for ASND.
In another report released on March 10, TipRanks – Google also upgraded the stock to a Buy with a $264.00 price target.